The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Value Trend Is Expected For The Focal Segmental Glomerulosclerosis Market From 2026 To 2030?
The focal segmental glomerulosclerosis market size has experienced substantial growth recently. It is forecast to rise from $1.57 billion in 2025 to $1.69 billion in 2026, showing a compound annual growth rate (CAGR) of 7.6%. The expansion witnessed in previous periods is attributable to the prevalence of proteinuria, the burden of chronic kidney disease, the usage of corticosteroids, the broadening of nephrology clinics, and the development of dialysis infrastructure.
The focal segmental glomerulosclerosis market is anticipated to experience robust growth over the next few years. It is projected to expand to $2.24 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.2%. This growth during the forecast period can be attributed to factors such as precision nephrology, the discovery of early disease biomarkers, advancements in biologic drug development, the expansion of transplant programs, and increased funding for rare kidney diseases. Significant trends expected during this period include a heightened focus on targeted immunosuppressive therapy, the increasing adoption of combination drug regimens, broader early diagnostic screening initiatives, a growing utilization of renin-angiotensin system inhibitors, and enhanced kidney transplant preparedness.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24541&type=smp
What Are The Main Drivers Accelerating The Growth Of The Focal Segmental Glomerulosclerosis Market?
The increasing incidence of kidney diseases is expected to propel the growth of the focal segmental glomerulosclerosis market going forward. Kidney diseases are conditions that compromise the function and structure of the kidneys, thereby hindering their capacity to filter waste, regulate fluids, and manage essential bodily functions. The rising prevalence of kidney diseases is predominantly attributed to diabetes, as prolonged elevated blood sugar levels can damage the kidneys’ filtering units, leading to diabetic nephropathy. Focal segmental glomerulosclerosis signifies the progressive scarring of kidney filters, acting as a crucial indicator and target for the understanding, diagnosis, and management of chronic kidney diseases. For instance, data from August 2025, provided by the American Kidney Fund, a U.S.-based nonprofit organization, indicates that 35.5 million Americans are living with chronic kidney disease (CKD), about 815,000 Americans are living with kidney failure, and nearly 555,000 Americans are on dialysis. Consequently, the growing prevalence of kidney diseases is driving the focal segmental glomerulosclerosis market.
How Is Segment Classification Applied In The Focal Segmental Glomerulosclerosis Market?
The focal segmental glomerulosclerosis market covered in this report is segmented –
1) By Disease Type: Primary Focal Segmental Glomerulosclerosis, Secondary Focal Segmental Glomerulosclerosis
2) By Treatment: Drug Therapy, Dialysis, Kidney Transplant, Other Treatments
3) By Drug Class: Immunosuppressants, Angiotensin Inhibitors, Corticosteroids
4) By Route Of Administration: Oral, Parenteral
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Primary Focal Segmental Glomerulosclerosis: Idiopathic Focal Segmental Glomerulosclerosis, Genetic Or Familial Focal Segmental Glomerulosclerosis, Collapsing Variant, Tip Lesion Variant, Cellular Variant, Perihilar Variant
2) By Secondary Focal Segmental Glomerulosclerosis: Virus-Associated Focal Segmental Glomerulosclerosis, Drug-Induced Focal Segmental Glomerulosclerosis, Adaptive Or Compensatory Focal Segmental Glomerulosclerosis, Other Secondary Causes
What Trends Are Affecting The Focal Segmental Glomerulosclerosis Market Dynamics?
Leading companies within the focal segmental glomerulosclerosis market are concentrating on developing advanced therapies, such as non-immunosuppressive oral medication, to enhance patient outcomes and mitigate treatment adverse effects. A non-immunosuppressive oral medication is an orally administered drug that addresses disease without impairing the immune system, thereby aiding in the management of focal segmental glomerulosclerosis by directly targeting kidney damage and bypassing immune-related complications. For example, in May 2025, Travere Therapeutics Inc., a US-based biopharmaceutical company, secured traditional approval from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). FILSPARI is a first-in-class therapy that operates by simultaneously blocking both the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R). This dual mechanism effectively reduces proteinuria in conditions such as FSGS and IgA nephropathy. In comparison to existing therapies, FILSPARI delivers superior kidney protection while maintaining an excellent safety profile.
Which Industry Players Are Present In The Focal Segmental Glomerulosclerosis Market?
Major companies operating in the focal segmental glomerulosclerosis market are Pfizer Inc., Merck And Co. Inc., Sanofi S.A., Eli Lilly and Company, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Mallinckrodt ARD LLC, Kyowa Kirin Co. Ltd., Aurinia Pharmaceuticals Inc., Travere Therapeutics Inc., Eledon Pharmaceuticals Inc., ZyVersa Therapeutics Inc., Complexa Inc., Certa Therapeutics, Delta 4 GmbH, Dimerix Limited, Goldfinch Bio Inc., Oraxion Therapeutics Inc., Variant Pharmaceuticals Inc.
Access The Complete Focal Segmental Glomerulosclerosis Market Report:
Which Geographic Region Represents The Largest Focal Segmental Glomerulosclerosis Market Share?
North America was the largest region in the focal segmental glomerulosclerosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the focal segmental glomerulosclerosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Focal Segmental Glomerulosclerosis Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=24541&type=smp
Browse Through More Reports Similar to the Global Focal Segmental Glomerulosclerosis Market 2026, By The Business Research Company
Focal Segmental Glomerulosclerosis Drugs Market Report 2026
Kidney Disease Market Report 2026
https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report
Rare Kidney Diseases Market Report 2026
https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model